Similar articles

• Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.

  Koukourakis MI. Koukourakis MI. Semin Oncol. 2002 Dec;29(6 Suppl 19):42-6. doi: 10.1053/sonc.2002.37359. Semin Oncol. 2002. PMID: 12577243 Review.
• Established and emerging uses of cytoprotection in head and neck cancer.

  Rosenthal DI. Rosenthal DI. Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):129-30. doi: 10.1001/archotol.132.2.129. Arch Otolaryngol Head Neck Surg. 2006. PMID: 16490868 No abstract available.
• Future development of amifostine as a radioprotectant.

  Werner-Wasik M. Werner-Wasik M. Semin Oncol. 1999 Apr;26(2 Suppl 7):129-34. Semin Oncol. 1999. PMID: 10348272 Review.
• [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].

  Huang R, Yu H, Kuang A. Huang R, et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002 Dec;19(4):708-11. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2002. PMID: 12561384 Review. Chinese.
• The role of amifostine as a radioprotector.

  Wasserman TH, Brizel DM. Wasserman TH, et al. Oncology (Williston Park). 2001 Oct;15(10):1349-54; discussion 1357-60. Oncology (Williston Park). 2001. PMID: 11702962 Review.